Sign in with Google
SmPC
Join our community on Telegram!
Join the biggest community of Pharma students and professionals.
SmPC stands for Summary of Product Characteristics. It is the official regulatory document approved in the European Union that describes the conditions of use, safety profile, and scientific data of a medicinal product. It serves a role similar to the USPI in the United States, but it follows European regulatory structure and format.
SmPC is governed by the European Medicines Agency and national competent authorities of EU member states under Directive 2001/83/EC. It is mandatory for all medicinal products authorized through centralized, decentralized, mutual recognition, or national procedures.
Regulatory Foundation
| Parameter | Details |
|---|---|
| Governing Authority | European Medicines Agency and National Authorities |
| Legal Basis | Directive 2001/83/EC |
| Applicable Applications | MAA (Marketing Authorisation Application) |
| Region | European Union |
| Target Audience | Healthcare professionals |
Purpose of SmPC
The SmPC provides scientifically evaluated information for healthcare professionals to ensure safe and effective use of a medicinal product. It defines therapeutic indications, dosage, contraindications, warnings, pharmacology, and clinical evidence. It also forms the legal basis for product promotion and pharmacovigilance activities within the EU.
Structure of SmPC
The SmPC follows a standardized format defined by the European Commission guideline. It consists of numbered sections from 1 to 10.
| Section Number | Title |
|---|---|
| 1 | Name of the Medicinal Product |
| 2 | Qualitative and Quantitative Composition |
| 3 | Pharmaceutical Form |
| 4 | Clinical Particulars |
| 5 | Pharmacological Properties |
| 6 | Pharmaceutical Particulars |
| 7 | Marketing Authorisation Holder |
| 8 | Marketing Authorisation Number(s) |
| 9 | Date of First Authorisation/Renewal |
| 10 | Date of Revision of the Text |
Section 4 Clinical Particulars is the most detailed part and includes therapeutic indications, posology and method of administration, contraindications, special warnings and precautions, interactions, fertility/pregnancy/lactation, effects on ability to drive, undesirable effects, and overdose.
Section 5 Pharmacological Properties includes pharmacodynamic properties, pharmacokinetic properties, and preclinical safety data.
Section 6 Pharmaceutical Particulars includes information on excipients, incompatibilities, shelf life, storage conditions, container type, and instructions for disposal.
SmPC versus USPI
| Parameter | SmPC | USPI |
|---|---|---|
| Region | European Union | United States |
| Regulator | European Medicines Agency | U.S. Food and Drug Administration |
| Legal Basis | EU Directive 2001/83/EC | 21 CFR 201.56 and 201.57 |
| Format | Sections 1–10 | Highlights + Sections 1–17 |
| Application Type | MAA | NDA / ANDA |
Lifecycle Management
SmPC is updated through variations submitted to regulatory authorities. Variations are categorized as Type IA, Type IB, or Type II depending on the significance of the change. Safety updates are often linked with periodic safety update reports and pharmacovigilance obligations.
Role in Regulatory Affairs and Medical Writing
SmPC drafting requires strong understanding of EU guidelines, clinical data interpretation, and regulatory language. Medical writers prepare SmPC content during initial marketing authorization and post-approval variations. Regulatory professionals ensure alignment between SmPC, patient leaflet, and labeling components across EU member states.
